Safe Pass Raw Materials Powder Rivastigmine Tartrate CAS 129101-54-8 For Alzheimer Disease

MF: C18H28N2O8

MW: 400.42

Synonyms: 3-[(S)-1-(Dimethylamino)ethyl]phenyl N-Ethyl-N-methylcarbamate L-Tartrate N-Ethyl-N-methylcarbamic Acid 3-[(S)-1-(Dimethylamino)ethyl]phenyl Ester L-Tartrate;(S)-3-(1-(diMethylaMino)ethyl)phenyl ethyl(Methyl)carbaMate (2R,3R)-2,3-dihydroxysuccinate;RivastigMine-d6 Hydrogen Tartrate;N-ethyl-N-methyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester, (2R,3R)-2,3-dihydroxybutanedioate (1:1);Rivastigmine tartrate (S)-N-Ethyl-3-[(1-dimethylamino)ethyl]-N-methylphenylcarbamate hydrogen tartrate;N-Ethyl-N-methyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester tartrate;Rivastigmine for system suitability;S-Rivastigmine tartrate

Melting point:123-1250C

alpha D20 +4.7° (c = 5 in ethanol)

storage temp. -20°C Freezer

solubility H2O: soluble15mg/mL, clear

color white to beige

Abstract

(1) Rivastigmine is mainly through hydrolysis cholinesterase metabolism, cytochrome P450 isozymes are rarely involved in its metabolism. Therefore, the product and by other drugs metabolized by these enzymes does not exist pharmacokinetic interactions.

(2) study in healthy volunteers found the product (a single dose of 3mg) with digoxin, warfarin, diazepam or fluoxetine, have no pharmacokinetic interactions. Warfarin induced by prothrombin time extension are not affected by this product. After combination of digoxin and the product found no adverse impact on cardiac conduction.

(3) In clinical studies of patients with Alzheimer’s disease (AD), the goods and some commonly used prescription drugs combined, such as antacids, antiemetics, hypoglycemic agents, β-blockers, calcium channel blockers agents, inotropic agents, anti-angina drugs, non-steroidal anti-inflammatory drugs, estrogens, analgesics, tranquilizers, antihistamines, etc., and risk of clinically relevant adverse reaction does not increase

(4) In view of the pharmacokinetic effect of this product, this product should not be used in combination with other cholinergic drugs, it may interfere with the activity of anticholinergic drugs.

(5) There is no experience of this product with anti Parkinson drugs, anti anxiety drugs (except for stability), antipsychotic drugs, antiepileptic drugs, antidepressant drugs.

(6) rivastigmine tartrate as a cholinesterase inhibitor, during anesthesia, it can be used to enhance succinylcholine-type muscle relaxant effect.

Benefits

Rivastigmine improves the function of nerve cells in the brain. It works by preventing the breakdown of a chemical that is important for the processes of memory, thinking, and reasoning. People with dementia usually have lower levels of this chemical.

Rivastigmine is used to treat mild to moderate dementia caused by Alzheimer’s or Parkinson’s disease.

Rivastigmine may also be used for purposes not listed in this medication guide.

COA